Pharmaceuticals
World Orphan Drug Alliance Welcomes Specialised Therapeutics
* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. * ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA). * Wor...
2023-09-08 04:00
1728
SOAP Health and AESOP Technology Unite to Provide Advanced AI Solutions for Clinical Decision-Support and Medical Coding
SOAP Health's conversational AI for medical encounters, risk and symptom assessment, and documentation integrates with AESOP Technology's electronic medical record data analysis for clinical decision optimization, coding, and productivity. BOCA RATON, Fla., Sept. 7, 2023 /PRNewswire/ -- SOAP Hea...
2023-09-07 21:00
1598
Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
- Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app - SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's 2023 STRI...
2023-09-07 20:00
1811
Isotopia Issues a call to action to the radionuclide Therapy industry.
PETAH TIKVA, Israel, Sept. 6, 2023 /PRNewswire/ -- Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes therapeutic and diagnostic radioactive isotopes. "If you are in the Lu-177 field, don't miss this information." The Lu-177 radiopharmaceutical...
2023-09-06 20:40
1638
Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non- opioid pain management patch in Abdominoplasty Surgery.
SAN JOSE, Sept. 6, 2023 /PRNewswire/ -- Teikoku Pharma USA, a global pharmaceutical company, today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 4-day dexmedetomidine transdermal patch for Post Surgical Pain. The double-blind, placebo-controlled, single-...
2023-09-06 20:06
2051
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
* The first and only anti-PD-1 antibody approved for treating cervical cancer inChina * ORR of 27.8%, mPFS of 3.7m, and mOS of 16.8m achieved as monotherapy with best-in-class potential * A Phase 3 trial (VICT-004) of zimberelimab in combination with platinum-based chemotherapy +/- bevacizu...
2023-09-06 19:00
1425
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment and correlates with the increased rate of HBsAg loss Saf...
2023-09-06 18:45
2436
CANbridge to Participate in Two Investor Conferences in September
BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today a...
2023-09-06 16:06
1643
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held inVienna from 9...
2023-09-06 14:18
1702
MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study
GENEVA, Sept. 6, 2023 /PRNewswire/ -- The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where ...
2023-09-06 08:00
1843
MALAYSIA HEALTHCARE TRAVEL COUNCIL SELECTS MAYO CLINIC TO PROVIDE STRATEGIC COUNSEL TO FURTHER ADVANCE MEDICAL EXCELLENCE IN MALAYSIA
PUTRAJAYA, Malaysia, Sept. 5, 2023 /PRNewswire/ -- Malaysia Healthcare Travel
Council (MHTC), an agency established under the purview of Ministry of Health
Malaysia, has officially announced the successful establishment of a Memorandum
of Understanding (MoU) with US-basedMayo Clinic
2023-09-05 22:37
2138
YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference
GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious di...
2023-09-05 20:30
1636
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages. Compared with other commercially available hyaluronidase products, Tergase® showed no incidence of anti-drug antibodies (ADA). The occurrence of ADA is known ...
2023-09-05 20:00
1306
I-Mab Announces Upcoming Participation at September Conferences
ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies an...
2023-09-05 20:00
1421
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
* Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform * ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data * ACM is in partnering d...
2023-09-05 14:00
1714
GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)
* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality of pharmacokinetic, pharmacodynamic, and immunogenicity data from bioanalytic testing YONGIN, South Korea, Sept. 4, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, annou...
2023-09-05 09:57
1347
Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with Springer Nature
* The program is a part of the Seegene OneSystemTM business aimed at creating a 'world free from all diseases' * Collaborating with clinical researchers worldwide, Seegene will share its technologies and enable researchers to develop syndromic qPCR assays SEOUL, South Korea, Sept. 4, 2023 /PR...
2023-09-04 21:00
2297
National University Health System Launches World's First Public Hospital's Healthy Longevity Clinic at Alexandra Hospital
SINGAPORE, Sept. 2, 2023 /PRNewswire/ -- The National University Health System
(NUHS), NUS Yong Loo Lin School of Medicine andAlexandra Hospital (AH
2023-09-02 13:00
3531
ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors
SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignan...
2023-09-02 00:00
3180
Adicon Holdings Limited (9860.HK): Continuous growth in Core Operations, Consistent Profitability Enhancement
HANGZHOU, China, Sept. 1, 2023 /PRNewswire/ -- Adicon Holdings Limited (the "Company" or "Adicon"), one of the largest independent clinical laboratory (ICL) service providers listed on the Stock Exchange ofHong Kong (SEHK), has released its interim results for the first half of 2023. As a leading...
2023-09-01 21:30
5635
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 274 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13780
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9866
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8334
